November 7, 2001 |
Ivax Corp. may lose its right to sell a generic form of Bristol-Myers Squibb Co.'s Taxol cancer drug after an appeals court Tuesday said the Food and Drug Administration erred in approving the generic. Ivax shares plunged as much as 11% and Bristol-Myers shares rose. A third drug maker, American BioScience Inc., holds a patent on Taxol, and successfully argued to the Circuit Court of Appeals for the District of Columbia that the FDA improperly approved the generic.
March 31, 2001 |
Ivax Corp. faces a revived legal challenge to its generic version of the top-selling Taxol cancer drug, after a federal appeals court told a trial judge to reexamine the Food and Drug Administration's approval of the Ivax product. The ruling is the latest in a multifaceted legal fight involving Ivax, Taxol manufacturer Bristol-Myers Squibb Co. and American BioScience Inc., which says it has a patented method to reduce the drug's side effects. The U.S. Court of Appeals for the D.C.
November 22, 2000 |
Generic drug maker Ivax Corp. said it has formed a definitive agreement to acquire Long Beach-based business-to-business company B2bstores.com for an undisclosed amount in a move to take its Ivax Diagnostics unit public. The Net operations of B2bstores.com, which laid off employees and slashed spending in August, would be discontinued. Ivax would gain B2bstores.com's assets.
October 26, 2000 |
Chemical giant DuPont Co. said Wednesday that third-quarter operating earnings fell 14% because of surging raw material costs and the weak euro. It said those same problems could hurt it over the remainder of the year. DuPont said operating earnings declined to $537 million, or 51 cents a share, from $625 million, or 59 cents, a year earlier. Consolidated revenue was flat at $6.4 billion.
October 13, 2000
* Germany's Deutsche Bank said it reached an agreement to acquire the 84% of National Discount Brokers Group Inc. it does not already own for $840 million, or $49 a share, a deal that values the brokerage at more than $1 billion. * * Ivax Corp., which makes a generic version of the cancer-fighting drug Taxol, said it would acquire the Mexico City-based pharmaceutical company Laboratorios Fustery for an undisclosed amount of cash and stock.
October 4, 2000 |
A federal judge cleared the way for Ivax Corp. to sell a generic version of Bristol-Myers Squibb Co.'s breast cancer drug Taxol. U.S. District Judge Colleen Kollar-Kotelly in Washington rejected a request by Santa Monica-based American BioScience Inc. that was aimed at blocking the generic version.